New Protocol for Evaluating Maximum Inspiratory Pressure: Concurrent Validity and Test-Retest Reliability
Physical Therapy · 2024
DOI: 10.1093/ptj/pzae124 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Physical Therapy, 2024. Verfasst von Ibai López-de-Uralde-Villanueva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Rehabilitation and Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, Instituto de Investigación Sanitaria del H…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
The purpose of this study was to validate a maximum inspiratory pressure (MIP) test protocol based on the principles of the 1-repetition maximum (1RM) test, assess its test-retest reliability, and establish minimal detectable change (MDC) in individuals with chronic obstructive pulmonary disease (COPD).
Methods
Forty-nine individuals with COPD were included in the study, of whom 44 individuals attended 2 appointments separated by 7 to 10 days for test-retest reliability. The MIP test was performed using a threshold valve device (1RM-based protocol) and the digital manometer (reference test). The 1RM-based protocol consisted of an incremental phase (inspiratory load increase [10 cm H2O] to achieve respiratory failure) and an approach phase (load halfway between the lowest failed attempt and the last valid attempt was prescribed).
Results
The concurrent validity of the 1RM-based protocol for the MIP test was good with respect to the reference test (day 1, intraclass correlation coefficient [ICC] = 0.81; day 2, ICC = 0.85). The test-retest reliability was excellent (ICC = 0.92), with a standard error of measurement of 6.3 cm H2O and a MDC of 17.5 cm H2O.
Conclusion
This study validated a new 1RM-based protocol for the MIP test using an inspiratory muscle training (IMT) device in individuals with COPD, showing good concurrent validity compared with the reference test, as well as excellent test-retest reliability. The MDC reported can be interpreted and applied in the clinical setting. Impact There was a need for developing new, inexpensive, simple, and feasible methods for the MIP test. The validation of the 1RM-based protocol addresses this issue, allowing for the appropriate prescription of IMT, favoring its widespread use in people with COPD, and therefore improving their physical therapist care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Rehabilitation and Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Complutense University of Madrid,…
- Servicio de Rehabilitación, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
- Pulmonology Department, IIS-Jiménez Díaz Foundation, ISCIII-CIBERES, Madrid, Spain.
ORCID-Profile: Raúl Fabero-Garrido, Tamara Del Corral
Zitieren
APA
López-de-Uralde-Villanueva, I., Fabero-Garrido, R., Rodríguez de Rivera, E. A., Santana, R., Gotera-Rivera, C., Peces-Barba, G., & Del Corral, T. (2024). New Protocol for Evaluating Maximum Inspiratory Pressure: Concurrent Validity and Test-Retest Reliability. Physical Therapy. https://doi.org/10.1093/ptj/pzae124
Vancouver
López-de-Uralde-Villanueva I, Fabero-Garrido R, Rodríguez de Rivera EA, Santana R, Gotera-Rivera C, Peces-Barba G, et al. New Protocol for Evaluating Maximum Inspiratory Pressure: Concurrent Validity and Test-Retest Reliability. Physical Therapy. 2024. doi:10.1093/ptj/pzae124
BibTeX
@article{LpezdeUraldeVillanueva2024,
author = {López-de-Uralde-Villanueva, Ibai and Fabero-Garrido, Raúl and Rodríguez de Rivera, Elena Alonso and Santana, Rafael and Gotera-Rivera, Carolina and Peces-Barba, Germán and Del Corral, Tamara},
title = {New Protocol for Evaluating Maximum Inspiratory Pressure: Concurrent Validity and Test-Retest Reliability},
journal = {Physical Therapy},
year = {2024},
doi = {10.1093/ptj/pzae124}
}
EUVIMED